ONCOMETHYLOME DEALS

[BIZ/LIFE-SCI: Liège, April 2]
OncoMethylome Sciences (Onco) expects to achieve a number of important deals this year, primarily in the area of colorectal cancer screening and personalized treatment. Two contracts are expected to be concluded with American service laboratories for the launching of products in the United States. Onco has recorded a loss of EUR 7.4m over the past year. In total the company achieved revenues of EUR 2.8m, primarily as a result of payments from Schering-Plough and Veridex LLC (a subsidiary of Johnson & Johnson.
http://www.express.be/